The Medicine and Healthcare products Regulatory Agency (MHRA) has cautioned men on valproate to talk to their healthcare professional about their treatment,
if they want to start a family in the next year.
The warning came after a new study, commissioned by the European Medicines Agency, suggested that children fathered by men who took the anti-seizure medicine in
the three months prior to conception may be at higher risk of developing neurodevelopmental disorders.
Around five in 100 children born to fathers treated with valproate around conception were diagnosed with a neurodevelopmental disorder, compared to three in
100 children whose fathers were taking other antiseizure medicines (lamotrigine or levetiracetam).
However, the risk is believed to be much smaller than the risk associated with valproate in pregnancy.